Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Theravance sales and marketing update

Theravance relaunched Vibativ telavancin in the U.S. almost two years after distribution was placed on hold in November

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE